Leukocyte 8-hydroxydeoxyguanosine (8OHdG) is an indicator of oxidative stress, impaired metabolism, and mitochondrial dysfunction, features that have been implicated in Huntington disease (HD). Increased levels of 8OHdG have been reported in the caudate, parietal cortex, and peripherally in the serum and leukocytes, in patients diagnosed with HD. However, little is known about levels in prodromal patients and changes that might occur as the disease progresses. To address these issues, 8OHdG was tracked over time for a subset of participants enrolled in the PREDICT-HD study. Participants were stratified into four groups based on proximity to HD diagnosis at study entry: Controls (gene-negative individuals), Low (low probability of nearfuture diagnosis), Medium, and High. Blood samples were analyzed using Liquid Chromatography Electrochemical Array, and for comparison purposes, a separate cross-sectional sample was analyzed using liquid chromatography coupled with multiple-reaction-monitoring mass spectrometry. Longitudinal data analysis showed that initial status (at study entry) and annual rate of change varied as a function of proximity group, adjusting for sex, education, age at study entry, and site effects. Overall levels were lowest for the Control group and highest for the High group, and the rate of increase varied in a similar manner. The finding that 8OHdG concentrations increased as a function of proximity to projected disease diagnosis and duration indicates support for the continued assessment of 8OHdG as a robust clinical HD biomarker.
Introduction
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder of the brain caused by the trinucleotide cytosineadenine-guanine (CAG) expansion in the gene of the protein huntingtin. There is currently no cure and the few treatments available are for symptom modification. Clinical diagnosis or phenoconversion is often based on the presence of motor symptoms consistent with the disease phenotype and most commonly occur during the fourth decade of life (Langbehn et al., 2004) . In addition to motor deterioration, declines in cognition and psychiatric deficits are common (Duff et al., 2007; Paulsen et al., 2008; Stout et al., 2011; Tabrizi et al., 2009) .
Identification of the gene responsible for HD (The Huntington's Disease Collaborative Research Group, 1993) has made it possible to identify prodromal research participants who are gene-positive, but
are not yet exhibiting clinical motor manifestations sufficient for clinical diagnosis. Research emphasis has since shifted to the development of clinical trials for possible disease-modifying treatments in prodromal persons (Paulsen et al., 2010b) , prior to the disease consequences of functional decline, brain atrophy, and adverse clinical symptoms. Investigations with prodromal HD participants allow researchers to gain valuable insight into pathogenesis through phenoconversion and beyond, the understanding of which could potentially lead to intervention measures preventing disease manifestation (Ross and Tabrizi, 2011) . Despite ample advances in the characterization of clinical and imaging changes in prodromal HD, few studies have identified possible biomarkers that might be useful in successfully monitoring therapeutic intervention efficacy. Aggressive research in the identification and validation of possible biomarkers for HD is critical to efforts to devise treatments for this relentless brain disease.
One biomarker of interest is leukocyte 8-hydroxydeoxyguanosine (8OHdG), which is an indicator of oxidative stress, impaired metabolism, and mitochondrial dysfunction. Such features have been implicated in Neurobiology of Disease 46 (2012) [625] [626] [627] [628] [629] [630] [631] [632] [633] [634] Abbreviations: 8OHdG, 8-hydroxydeoxyguanosine; HD, Huntington disease; CAG, cytosine-adenine-guanine; ROS, radical oxygen species; UHDRS, Unified Huntington's Disease Rating Scale; DCL, diagnostic confidence level; CAP, CAG length/age product; LCECA, Liquid Chromatography Electrochemical Array; MRM, multiple-reaction-monitoring; PPD, pharmaceutical product development; LMER, linear mixed effects regression; LRT, likelihood ratio test; AIC, Akaike's information criterion; LR, linear regression. 
